Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.28 USD

201.28
1,008,049

+0.81 (0.40%)

Updated Nov 5, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

Kalyan Nandy headshot

Top Research Reports: Chevron, AbbVie, Phillips 66 & More

Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), AbbVie (ABBV) and Phillips 66 (PSX).

Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y

Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View

AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.26% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca (AZN) Jumps: Stock Rises 5.7%

AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up

AbbVie's (ABBV) second-quarter 2019 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

Christopher Vargas headshot

Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?

Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Should You Buy AbbVie (ABBV) Ahead of Earnings?

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

Sanghamitra Saha headshot

Use Rising P/E Strategy to Buy 5 Winning Stocks

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

Kinjel Shah headshot

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.